Avicanna Files Complete Patent Specifications Relating to a Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy
20. Oktober 2022 07:30 ET
|
Avicanna Inc.
TORONTO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna Introduces a New Medical Cannabis Education Online Portal, “Avicenna Academy” for Health Care Professionals
18. Oktober 2022 07:30 ET
|
Avicanna Inc.
The education portal provides modules, case studies and other resources related to medical cannabis for Health Care Professionals Established with the support of experts in the fields of pain...
Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto
15. September 2022 09:09 ET
|
Avicanna Inc.
Dr. Mac Burnham’s team will explore Avicanna’s drug candidate and its proprietary combination of cannabinoids in pre-clinical model for seizures. Avicanna further expands its current research and...
Avicanna Announces Results of Annual General and Special Meeting
01. September 2022 07:30 ET
|
Avicanna Inc.
TORONTO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna Announces Closing of Strategic Private Placement
17. August 2022 17:00 ET
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna Reports Q2 2022 Financial Statement
15. August 2022 17:00 ET
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna and Ei. Ventures Enter into an Agreement to Develop and Commercialize Adaptogen Nutraceuticals
20. Juli 2022 07:30 ET
|
Avicanna Inc.
Psilly™ branded functional fungi-based products will be developed by Avicanna utilizing Avicanna’s proprietary delivery systems and scientific platform TORONTO, July 20, 2022 (GLOBE...
Avicanna Announces Date of Upcoming Annual General and Special Meeting of Shareholders
11. Juli 2022 17:15 ET
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna Completes its First Commercial Export of its Derma-Cosmetics Brand Pura H&W™ into the European Union
07. Juli 2022 07:30 ET
|
Avicanna Inc.
The exclusive distribution agreement with Bio-Gate AG includes 5 SKUs from Pura H&W’s evidence-based derma-cosmetics portfolio Initial portfolio launch is planned for Germany, Austria, and...
Avicanna Sells Stake in Majority-Owned Colombian Subsidiary Sativa Nativa
24. Juni 2022 07:30 ET
|
Avicanna Inc.
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and...